(4-Acetyl-phenylmercapto)-essigsaeure | 17067-15-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (4-Acetyl-phenylmercapto)-essigsaeure
• 英文别名: (4-Acetylphenylthio)acetic acid；2-(4-acetylphenyl)sulfanylacetic acid
• CAS: 17067-15-1
• 化学式: C₁₀H₁₀O₃S
• 分子量: 210.254
• InChiKey: GQBFZYQARKRSKH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  79.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (4-Acetyl-phenylmercapto)-essigsaeure 在 硫酸 、 双氧水 作用下， 生成 1,1'-(二硫代二-4,1-亚苯基)二-乙酮
  参考文献：
  名称：

  Electrophilic Substitution of the Benzenethiols. II. Acylbenzene- and Acyltoluenethiols^1,2

  摘要：

  DOI：

  10.1021/jo01046a035
• 作为产物：
  描述：

  4-Acetyl-phenyl-diazonium 在 sodium carbonate 作用下， 生成 (4-Acetyl-phenylmercapto)-essigsaeure
  参考文献：
  名称：

  Riess; Frankfurter, Monatshefte fur Chemie, 1928, vol. 50, p. 71

  摘要：

  DOI：

文献信息

• Retinoid x receptor modulators
  申请人：——

  公开号：US20040167160A1

  公开（公告）日：2004-08-26

  The present invention is directed to compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof: (I). The invention is also directed to pharmaceutical compositions, methods of use and methods of making compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof.

  本发明涉及由结构式（I）表示的化合物及其药用可接受的盐、溶剂合物和水合物：（I）。该发明还涉及由结构式（I）表示的化合物及其药用可接受的盐、溶剂合物和水合物的药物组合物、使用方法和制备方法。
• Chalcone derivatives and their use to treat diseases
  申请人：Ni Liming

  公开号：US20060189549A1

  公开（公告）日：2006-08-24

  The invention relates to compounds, pharmaceutical compositions and methods of using compounds of the general formula or its pharmaceutically acceptable salt or ester, wherein the substituents are defined in the application.

  本发明涉及一般式化合物、药物组合物及使用该一般式化合物或其药学上可接受的盐或酯的方法，其中取代基在申请中定义。
• Retinoid X receptor modulators
  申请人：Eli Lilly and Company

  公开号：US07348359B2

  公开（公告）日：2008-03-25

  The present invention is directed to compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof: (I). The invention is also directed to pharmaceutical compositions, methods of use and methods of making compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof.

  本发明涉及由结构式（I）表示的化合物及其药学上可接受的盐、溶剂和水合物：（I）。本发明还涉及由结构式（I）表示的化合物及其药学上可接受的盐、溶剂和水合物的制备方法、药物组合物和使用方法。
• Bi-functional complexes and methods for making and using such complexes
  申请人：Gouliaev Alex Haahr

  公开号：US11225655B2

  公开（公告）日：2022-01-18

  The present invention is directed to a method for the synthesis of a bi-functional complex comprising a molecule part and an identifier oligonucleotide part identifying the molecule part. A part of the synthesis method according to the present invention is preferably conducted in one or more organic solvents when a nascent bi-functional complex comprising an optionally protected tag or oligonucleotide identifier is linked to a solid support, and another part of the synthesis method is preferably conducted under conditions suitable for enzymatic addition of an oligonucleotide tag to a nascent bi-functional complex in solution.

  本发明涉及一种合成双功能复合物的方法，该复合物包括分子部分和识别分子部分的识别寡核苷酸部分。根据本发明的合成方法的一部分优选在一种或多种有机溶剂中进行，此时包含可选保护标签或寡核苷酸标识符的新生双功能复合物与固体支持物相连接，合成方法的另一部分优选在适合于将寡核苷酸标签酶加到溶液中的新生双功能复合物的条件下进行。
• Design and synthesis of benzofused heterocyclic RXR modulators
  作者：D.L. Gernert、D.A. Neel、M.F. Boehm、M.D. Leibowitz、D.A. Mais、P.Y. Michellys、D. Rungta、A. Reifel-Miller、T.A. Grese

  DOI：10.1016/j.bmcl.2004.03.073

  日期：2004.6

  Benzofused heterocyclic analogs of the RXR selective modulator I (LG101506) were synthesized, and tested for their ability to bind RXRalpha and activate RXR homo and heterodimers. Potency and efficacy were observed to be dependent upon the choice of heterocycle as well as the sidechain employed. (C) 2004 Published by Elsevier Ltd.